Loading ...
The most common agentscausingchemotherapy - associated nephrotoxicity
the second - linesettingthe combination chemotherapy with ACO
to be more practical than treatment with a single drug(passive) has been discoveredCombination chemotherapy
The expansion dose of the drugledin combination with chemotherapy
to be more effective than remedy with a single drug(passive) has been discoveredCombination chemotherapy
histology , age , comorbidity , and performance status(passive) might be influenced bycytotoxic combination chemotherapy
Use of extended field radiotherapy andhas ledcombination chemotherapy
by the exposure(passive) greatly influenced bya combination chemotherapy
bacteriacauseCombination chemotherapy
hair losscausedassociated with chemotherapy
The high dose treatments andresultedthe combination chemotherapy
the decisionto provokecombination chemotherapy
the concomitantsetup with combination chemotherapy
the choiceto provokecombination chemotherapy
H receptorsleadingin combination chemotherapy
the second - line NSCLCsettingin combination with chemotherapy
second - line NSCLCsettingin combination with chemotherapy
the choiceto provokemixture chemotherapy
mainly(passive) was ... composedpostoperative chemotherapy
to prevent the recurrence of cancer(passive) is mainly designedAdjuvant chemotherapy
to prevent recurrence of the disease , particularly distant recurrence(passive) is designedAdjuvant chemotherapy
this phenomenon should be taken into considerationwhen designingantimicrobial chemotherapy
The primary treatmentcausesnecessitates chemotherapy
to kill quickly dividing cells(passive) is designedChemotherapy
to kill all fast growing cells(passive) is designedChemotherapy
to kill fast - growing cells(passive) is designedChemotherapy
Cancer and cancers therapies for examplewill causechemotherapy
the factorsinfluencingneoadjuvant chemotherapy
to kill rapidly growing cells such as cancer cells but affects all rapidly growing cells(passive) is designedChemotherapy
to kill fast - growing cancer cells(passive) is designedChemotherapy
the P - gp cells(passive) caused bychemotherapy
to target rapidly dividing cells in a specific stage of cell division(passive) is designedChemotherapy
to kill rapidly dividing cells throughout the body(passive) is designedChemotherapy
to target frequently dividing cells and to inhibit their dividing mechanism(passive) is designedChemotherapy
to target rapidly dividing cancer cells in the body(passive) are designedChemotherapy
to kill cancer cells(passive) is designedChemotherapy
to kill fast - growing cells , like cancer cells(passive) is designedChemotherapy
to destroy the rapidly dividing cells(passive) is designedChemotherapy
to kill fast dividing cells(passive) is designedChemotherapy
Multimodal treatment including surgical resection , radiotherapy , andhas ledchemotherapy
a significant and persistent decrease in B - cell numberscauseda significant and persistent decrease in B - cell numbers
to an effective regimen of curative chemotherapy for Hodgkin?s disease and diffuse large cell lymphomasledto an effective regimen of curative chemotherapy for Hodgkin?s disease and diffuse large cell lymphomas
to an effective regimen of curative chemotherapy for Hodgkin 's disease and diffuse largeledto an effective regimen of curative chemotherapy for Hodgkin 's disease and diffuse large
to therapeutic failureledto therapeutic failure
to a significant longer overall survival ( OS ) and progression - free survival ( PFSledto a significant longer overall survival ( OS ) and progression - free survival ( PFS
substantial side effectcausingsubstantial side effect
alsoresultedalso
to full recoveryledto full recovery
to a full recoveryledto a full recovery
to bone marrow suppressioncould have contributedto bone marrow suppression
in significant prolongation of OS and time to progression and superior tumor response but more toxicity in women with metastatic breast cancer ( Carrick et al . 2009resultedin significant prolongation of OS and time to progression and superior tumor response but more toxicity in women with metastatic breast cancer ( Carrick et al . 2009
to similar toxicity rates as the standard therapyledto similar toxicity rates as the standard therapy
in a significant survival advantage in patients with advanced gastric cancerresultsin a significant survival advantage in patients with advanced gastric cancer
in improved survivals ( 2 - 5has resultedin improved survivals ( 2 - 5
in a higher response rate than single agent treatmentresultsin a higher response rate than single agent treatment
to an increase in the response rate and possibly survivalmight leadto an increase in the response rate and possibly survival
a complete clinical remissioncausesa complete clinical remission
greater tumour cell killcan causegreater tumour cell kill
to remission of the diseaseledto remission of the disease
in prolonged survival compared with just the combination of chemotherapy and radiation therapy.[15resultedin prolonged survival compared with just the combination of chemotherapy and radiation therapy.[15
to early changes inleadsto early changes in
in a significant survival advantageresultsin a significant survival advantage
in complete remissionresultedin complete remission
in complete remissionhas resultedin complete remission
in complete remissionresultingin complete remission
side effects(passive) caused byside effects
side effects(passive) caused byside effects
in vastly improved survival for some cancershas resultedin vastly improved survival for some cancers
to complete remission for certain types of cancercould leadto complete remission for certain types of cancer
in long term remissioncan resultin long term remission
to an even more dramatic responseledto an even more dramatic response
the tumor to shrinkcausesthe tumor to shrink
to an initial clinical responseledto an initial clinical response
to prolonged duration of remissionleadsto prolonged duration of remission
in no evidence of microscopic disease at the time of surgery in 50 % of enrolled patientswill resultin no evidence of microscopic disease at the time of surgery in 50 % of enrolled patients
in higher response ratescan resultin higher response rates
part remissioncausepart remission
to modest survival improvements ( 3 , 4has ledto modest survival improvements ( 3 , 4
to modest improvements in outcomehas leadto modest improvements in outcome
hearing loss , kidney failure and leukemiacan causehearing loss , kidney failure and leukemia